https://endpts.com/small-biotechs-with-big-drug-ambitions-threaten-to-upend-the-traditional-drug-launch-playbook/
This article isnt about a DMD drug. But rather a small biotech, with a headcount of less than 100 employees. that took a migraine drug through to approval by themselves. They had big pharma with competing drugs. but did ok. Interesting to read how the majority of investors were against the independent move. Share price might show they ended up doing ok as well.
https://endpts.com/small-biotechs-with-big-drug-ambitions-threate...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.005(3.85%) |
Mkt cap ! $121.7M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 13.5¢ | 13.0¢ | $378.0K | 2.903M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 516956 | 4 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |